Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Advances in Cancer Nanovaccines: A Focus on Colorectal Cancer Publisher Pubmed



Ghazizadeh Y1, 2 ; Salehi Shadkami H2, 3 ; Madani F4 ; Niknam S5 ; Adabi M4, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Nanomedicine Student Association (NMA), Student’s Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medical Science, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Institute of Nano Science and Nano Technology, University of Kashan, Kashan, Iran
  6. 6. Food Microbiology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Nanomedicine Published:2025


Abstract

Nanotechnology has revolutionized cancer treatment by providing innovative solutions through nanocancer therapies, nanovaccines, and nanoparticles. This review focuses on the application of these technologies in colorectal cancer (CRC), highlighting their progression from preclinical studies to clinical trials. Nanoparticles, including liposomes, silica, gold, and lipid nanoparticles, possess unique properties that enhance drug delivery, improve therapeutic efficacy, and minimize systemic toxicity. Additionally, nanovaccines are being developed to elicit robust immune responses against CRC cells. This paper offers a comprehensive overview of the current state of nanotechnology-based treatments for CRC, emphasizing key preclinical studies and clinical trials that demonstrate their potential. Furthermore, the review discusses the challenges faced in this field. It outlines future directions for research, underscoring the need for ongoing efforts to translate these promising technologies into practical clinical applications. © 2025 Informa UK Limited, trading as Taylor & Francis Group.